Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

January 6, 2025
PRESS RELEASE REGULATED INFORMATION 6 January 2025, 07:00 am CET / 01:00 am ET Webinar to discuss US commercial roll-out following FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024 alfapump has received PMA Approval[1] and FDA Breakthrough Device Designation Call participants include Dr. Saab, David Geffen...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES